{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:38Z","timestamp":1790109938398,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ando.2020.12.008","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T10:41:57Z","timestamp":1608979317000},"page":"15-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The risks of medical treatment of prolactinoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Frederic","family":"Castinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Albarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Amodru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Graillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Morange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2020.12.008_bib0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13023-016-0516-x","article-title":"The risks of overlooking the diagnosis of secreting pituitary adenomas","volume":"11","author":"Brue","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2020.12.008_bib0215","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2020.12.008_bib0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0225","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","article-title":"Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients","volume":"63","author":"Ferrari","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.008_bib0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.008_bib0240","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2020.12.008_bib0245","article-title":"Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia","author":"Stiles","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2020.12.008_bib0250","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1210\/jc.2019-00577","article-title":"Letter to the Editor: \u201cA meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline.\u201d","volume":"104","author":"Caputo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0255","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1210\/jc.2019-00704","article-title":"Response to Letter to the Editor: \u201cA meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline.\u201d","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2230-8210.81949","article-title":"Cabergoline-induced tricuspid regurgitation: case report and review of literature","volume":"15","author":"Bhat","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0265","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2265.2010.03973.x","article-title":"Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?","volume":"74","author":"Gu","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2020.12.008_bib0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1445-5994.2009.01920.x","article-title":"Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma","volume":"39","author":"Cawood","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/j.ando.2020.12.008_bib0275","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0280","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.008_bib0285","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline","author":"Stiles","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0290","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/jc.2016-2224","article-title":"A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline","volume":"101","author":"Drake","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0295","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1136\/heartjnl-2018-313082","article-title":"Cardiac auscultation poorly predicts the presence of valvular heart disease in asymptomatic primary care patients","volume":"104","author":"Gardezi","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ando.2020.12.008_bib0300","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERP-18-0069","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology","volume":"6","author":"Steeds","year":"2019","journal-title":"Echo Res Pract"},{"key":"10.1016\/j.ando.2020.12.008_bib0305","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1874306400903010090","article-title":"Pleuropulmonary toxicity of another Anti-Parkinson's drug: cabergoline","volume":"3","author":"Belmonte","year":"2009","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.ando.2020.12.008_bib0310","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-09-0989","article-title":"Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline","volume":"162","author":"Lafeber","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.008_bib0315","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease","volume":"104","author":"Ahlskog","year":"2011","journal-title":"Physiol Behav"},{"key":"10.1016\/j.ando.2020.12.008_bib0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.ando.2020.12.008_bib0325","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2020.12.008_bib0330","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.ando.2020.12.008_bib0335","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2020.12.008_bib0340","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ando.2020.12.008_bib0345","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2020.12.008_bib0350","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1530\/EJE-12-0198","article-title":"Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas","volume":"167","author":"Athanasoulia","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.008_bib0355","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00005537-200308000-00003","article-title":"Incidence, etiology, and management of cerebrospinal fluid leaks following trans-sphenoidal surgery","volume":"113","author":"Shiley","year":"2003","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ando.2020.12.008_bib0360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2265.2000.00901.x","article-title":"CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas","volume":"52","author":"Leong","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2020.12.008_bib0365","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1210\/jc.2007-0373","article-title":"Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features","volume":"92","author":"Suliman","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0370","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.surneu.2009.06.005","article-title":"Is surgical intervention frequently required for medically managed macroprolactinomas?. A study of spontaneous cerebrospinal fluid rhinorrhea","volume":"72","author":"de Lacy","year":"2009","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ando.2020.12.008_bib0375","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1055\/s-0039-1677686","article-title":"CSF rhinorrhea following medical treatment for prolactinoma: management and challenges","volume":"80","author":"Arimappamagan","year":"2019","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.ando.2020.12.008_bib0380","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2020.12.008_bib0385","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2174\/1871527311211080011","article-title":"Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review","volume":"11","author":"Carija","year":"2012","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.ando.2020.12.008_bib0390","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-16-0897","article-title":"MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment","volume":"176","author":"Eroukhmanoff","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2020.12.008_bib0395","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2013-1249","article-title":"The prevalence and natural history of pituitary hemorrhage in prolactinoma","volume":"98","author":"Sarwar","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.008_bib0400","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2265.2000.01039.x","article-title":"Optic chiasmal herniation\u2013an under recognized complication of dopamine agonist therapy for macroprolactinoma","volume":"53","author":"Jones","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2020.12.008_bib0405","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.wneu.2018.01.202","article-title":"Transnasal transsphenoidal elevation of optic chiasm in secondary empty sella syndrome following prolactinoma treatment","volume":"112","author":"Cobb MI-PH","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ando.2020.12.008_bib0410","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2265.2008.03364.x","article-title":"Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma","volume":"70","author":"Raverot","year":"2009","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:52:28Z","timestamp":1757717548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620313184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0003426620313184"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.008","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risks of medical treatment of prolactinoma","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}